Skip to main content
SpringerLink
Log in

Intensive Insulin Therapy in T2DM

  • Chapter
Type 2 Diabetes Mellitus

Part of the book series: Contemporary Endocrinology ((COE))

  • 3776 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Diabetes Association. Clinical Practice Recommendations 2007 Diabetes Care. 30(1), 2007.

    Google Scholar 

  2. Colwell JA. Controlling T2DM: are the benefits worth the cost? JAMA (2006).

    Google Scholar 

  3. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxy – lase reveal latent autoimmune diabetes mellitus in adults with a non-insulin dependent onset of disease. Diabetes 1993;42:359.

    Article  PubMed  CAS  Google Scholar 

  4. American Diabetes Association. Diabetes Dictionary. 2004. Available at http://www.diabetes.org/diabetes dictionary.jsp. Accessed on October 4, 2003.

    Google Scholar 

  5. Yu A, Wu PS, Edelman SV. The natural history of non-insulin dependent diabetes mellitus in a Filipino migrant population. Presented at the 3rd International Diabetes Federation, Western Pacific Regional Congress: Hong Kong; September 25–28, 1996.

    Google Scholar 

  6. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type 2 diabetics. Metabolic effects during a 6 mo outpatient trial. Diabetes Care 1993;161(1):21–31.

    Article  Google Scholar 

  7. Kuddlacek S, Schernthaner G. The effect of insulin treatment on HbA1c, body weight and lipids in type 2 diabetic patients with secondary failure to sulfonylureas. A five-year follow-up study. Horm Metab Res 1992;24:478.

    Article  Google Scholar 

  8. Roach P, Woodworth JR. Clinical Pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Clini Pharmacokinet 2002;41(13):1043–1057.

    Article  CAS  Google Scholar 

  9. Roach P, Yu L, Arora V for the Humalog Mix25 Study Group. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care 1999;22:1258–1261.

    Article  PubMed  CAS  Google Scholar 

  10. Jacobsen LV, Sogaard B, Ris A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble andprotamine-retarded insulin aspart. Eur J Clin Pharmacol 2000;56(5):399–403.

    Article  PubMed  CAS  Google Scholar 

  11. Boehm BO, Home PD, Brehend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 versus premixed human insulin 30/70 twice daily: a random mixed trial in type 1 and type 2 diabetic patients. Diabet Med 2002;19:393–399.

    Article  PubMed  CAS  Google Scholar 

  12. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH; Lispro Mixture-Glargine Study Group. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomiized, open label, crossover study in patients with T2DM beginning insulin therapy. Clin Ther 2004;26:2034–2044.

    Article  PubMed  CAS  Google Scholar 

  13. Raskin P, Allen E, Hollander P, Lewin A, Gabbay, RA, Hu P, Bode B, Garber A; INITIATE Study Group. Initiating insulin therapy in T2DM: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260–265.

    Article  PubMed  CAS  Google Scholar 

  14. Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, Jain R. Attainment of glycemic goals in T2DM with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 Study. Diabetes Obes Metab 2006;8:58–66.

    Article  PubMed  CAS  Google Scholar 

  15. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Initiation of Insulin in patients with Type 2 diabetes failing oral therapy. Diabetes Car. 2005;28:254–259.

    Article  CAS  Google Scholar 

  16. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and T2DM mellitus scientific review. JAMA 2003;289:2254–2264.

    Article  PubMed  CAS  Google Scholar 

  17. Naik RG, Palmer JP. Latent autoimmune diabetes in adults (LADA). Rev Endocr Metab Disord 2003;4:223–241.

    Article  Google Scholar 

  18. Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care 2001;24:1460–1467.

    Article  PubMed  CAS  Google Scholar 

  19. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005;28 Suppl 1:S4–S36.

    Article  Google Scholar 

  20. American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: The AACE System of Intensive Diabetes Self-Management – 2002 Update. Endocr Prac 2002;8 Suppl 1:40–82.

    Google Scholar 

  21. Yki-Jarvinen H, Dressler A, Ziemen M for the HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in T2DM. Diabetes Care 2000;23:1130–1136.

    Article  PubMed  CAS  Google Scholar 

  22. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE 901) in comparison with those off NPH insulin and placebo. Diabetes Care 2000;23:644–649.

    Article  PubMed  CAS  Google Scholar 

  23. Rosenstock J, Park G, Ziimmerman J; US insulin glargine (HOE 901) Type I Diabetes Investigator Group. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 ddiabetes on multiple daily insulin regimens. Diabetes Care 2000;23:1137–1142.

    Article  PubMed  CAS  Google Scholar 

  24. Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for T2DM. Diabetes Res Clin Pract 2004;66:193–201

    Article  PubMed  CAS  Google Scholar 

  25. Riddle MC, Rosenstock J, Gerich J, the Insulin Glargine Study Investigators. The Treat to Target Trial: randomized addidtion of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080–3086

    Article  PubMed  CAS  Google Scholar 

  26. Plodkowski RA, Edelman SV. The State of Insulin Pump Therapy-2002. Current Opinion in Endo and Diabetes. Vol 9:4 2002.

    Google Scholar 

  27. Plodkowski, RA, Edelman, SV, Physiologic Insulin Replacement with Continuous Subcutaneous Insulin Infusion: Insulin Pump Therapy. Clinical Diabetes 2006; 429–441.

    Google Scholar 

  28. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in T2DM mellitus. Diabetes 1985;34:222.

    Article  PubMed  CAS  Google Scholar 

  29. Raskin P, Boode BW, Marks JB, Hirsch IB, Weinstein RL, McGill JB, Peterson GE, Mudaliar SR, Reinhardt RR. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in T2DM: a randomized, parallel-group, 24-week study. Diabetes Care 2003;26(9):2598–2603.

    Article  PubMed  CAS  Google Scholar 

  30. EXUBERA (Package insert). New York, NY, Pfizer, Inc.

    Google Scholar 

  31. Rave K, Bott S, Heinemann L, et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care. 2005;28:1077–1062.

    Article  PubMed  CAS  Google Scholar 

  32. Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes. Results of a 6-month, randomized, comparative trial. Diabetes Care. 2004;27:2356–2356.

    Article  PubMed  CAS  Google Scholar 

  33. Dreyer M, for the Exubera Phase 3 Study Group. Efficacy and 2-year pulmonary safety data of inhaled insulin as adjunctive therapy with metformin or glibenclamide in type 2 diabetes patients poorly controlled with oral monotherapy. Diabetologia. 2004; 47(suppl 1): A44.

    Google Scholar 

  34. Fineberg SE, Kawabata T, Finco-Kent D, et al. Antibody responses to inhaled insulin in patients with type 1 and type 2 diabetes. J Clin Endocrinol Metabol. 2005;90:3287–3294.

    Article  CAS  Google Scholar 

Download references

Authors
  1. Steven V. Edelman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Duke University Medical Center Durham, NC, USA

    Mark N. Feinglos MD, CM  & M. Angelyn Bethel MD  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Edelman, S.V. (2008). Intensive Insulin Therapy in T2DM. In: Feinglos, M.N., Bethel, M.A. (eds) Type 2 Diabetes Mellitus. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-60327-043-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-043-4_12

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-794-5

  • Online ISBN: 978-1-60327-043-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation